The R&D tax incentive is now too costly and carries too much risk for a growing number of businesses, according to the chief technologist of a clinical trial software firm that has stopped using the program. Software claims under the research and development tax incentive (RDTI) have become increasingly contentious in recent years, with several … Continue reading R&D tax scheme too risky for software: Evado